Semma Therapeutics has appointed David Lebwohl to serve as chief medical officer. Lebwohl comes to the Cambridge, MA, regenerative medicine company from Novartis (NYSE: NVS), where he was senior vice president and franchise global program head of the CAR-T team.
In other moves, Semma named David DiGiusto its chief technology officer. DiGiusto comes to Semma from Stanford University. Last year, Semma raised $114 million in Series B financing to support development of a diabetes treatment that uses embryonic stem cells to make insulin-producing cells.